Literature DB >> 25376977

"Schizophrenia past clozapine": reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing.

F A Mustafa1, J G Burke1, S S Abukmeil1, J J Scanlon1, M Cox1.   

Abstract

INTRODUCTION: The clinical records of 190 patients with schizophrenia who discontinued clozapine between 1990 and 2012 in the county of Northamptonshire were examined, in an attempt to answer the following questions. Why do patients stop clozapine? What do physicians prescribe as an alternative? What is the mortality in this patient group?
METHODS: Patients' data were extracted using their electronic records, then analysed using descriptive statistical methods.
RESULTS: Non-compliance with treatment, or with the mandatory white blood cell monitoring, was the most common reason (55.3%) for clozapine cessation, followed by neutropaenia and other adverse effects (25.2%). Death (mean age 48 years) was the third most common reason (10%), with respiratory infections accounting for more than a quarter of the deaths. 13% of the patients had died (mean age 49 years) at some point following clozapine discontinuation. In terms of the alternative antipsychotic prescribing, olanzapine was the most commonly prescribed (37.1%) drug in patients who were still under the care of the local psychiatric service (n=121), at the time of data extraction. Clozapine had been reinstated in 19% of these patients. DISCUSSION: Our findings are generally consistent with previous studies, and they demonstrate the need for physicians to address their patients' concerns regarding clozapine treatment, and to effectively manage any adverse effects. Sialorrhea and constipation seem to be particularly of concern, as they may be linked to clozapine- related mortality. Olanzapine was the most commonly prescribed alternative to clozapine, which suggests that it may possibly have a role in refractory schizophrenia. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25376977     DOI: 10.1055/s-0034-1394397

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  18 in total

1.  Interaction between clozapine and oxcarbazepine: a case report.

Authors:  Hazel Yousra; Lebain Pierrick; Lecardeur Laurent; Debruyne Danièle
Journal:  Ther Adv Psychopharmacol       Date:  2016-12-15

2.  Strong Treatment Response and High Maintenance Rates of Clozapine in Childhood-Onset Schizophrenia.

Authors:  Lauren I Kasoff; Kwangmi Ahn; Peter Gochman; Diane D Broadnax; Judith L Rapoport
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-01-19       Impact factor: 2.576

3.  A Comprehensive Monitoring of Clozapine and Related Components in Clinical Practices. Saudi Arabian Scenario.

Authors:  Jisha M Lucca; Fatima M Al-Turaifi; Al-Mubayedh Safyah; Feras A Hamad Al-Awad
Journal:  Psychopharmacol Bull       Date:  2021-11-03

Review 4.  Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics.

Authors:  John Lally; Fiona Gaughran; Philip Timms; Sarah R Curran
Journal:  Pharmgenomics Pers Med       Date:  2016-11-07

5.  Rapid-onset clozapine-induced loss of glycaemic control: case report.

Authors:  Alejandro Porras-Segovia; Amir Krivoy; Mark Horowitz; George Thomas; Mark Bolstridge; Dragos Ion; Sukhwinder S Shergill
Journal:  BJPsych Open       Date:  2017-05-11

6.  Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation.

Authors:  Maxim Kuzin; Georgios Schoretsanitis; John M Kane; Christoph Hiemke; Michael Paulzen; Ekkehard Haen
Journal:  Clin Pharmacokinet       Date:  2020-10-01       Impact factor: 6.447

7.  Clozapine discontinuation in early schizophrenia: a retrospective case note review of patients under an early intervention service.

Authors:  Andrew Shaker; Rowena Jones
Journal:  Ther Adv Psychopharmacol       Date:  2017-11-19

8.  Reasons for discontinuing clozapine: A cohort study of patients commencing treatment.

Authors:  Sophie E Legge; Marian Hamshere; Richard D Hayes; Johnny Downs; Michael C O'Donovan; Michael J Owen; James T R Walters; James H MacCabe
Journal:  Schizophr Res       Date:  2016-05-19       Impact factor: 4.939

Review 9.  A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology.

Authors:  Jose de Leon; Can-Jun Ruan; Georgios Schoretsanitis; Carlos De Las Cuevas
Journal:  Psychother Psychosom       Date:  2020-04-14       Impact factor: 17.659

Review 10.  Use of Clozapine in the General Hospital.

Authors:  Feras Ali Mustafa
Journal:  Psychopharmacol Bull       Date:  2020-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.